ClinicalTrials.gg
CompletedNCT02708095Updated Nov 21, 2018Results posted

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of Baricitinib and Placebo in Systemic Lupus Erythematosus, sponsored by Eli Lilly and Company. Completed at 84 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-21.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.

Enrollment
7th of 11
314 · median 778
Started
2016
the only one that year
Phase 2
2 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 7th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 5th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have received a diagnosis of SLE at least 24 weeks prior to screening, meeting the American College of Rheumatology (ACR) 1982 revised criteria OR the 2012 Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria.
  • Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive anti-double-stranded deoxyribonucleic acid (dsDNA) as assessed by a central laboratory at screening.
  • Have a SLEDAI-2K score ≥4 based on clinical symptoms (not including lab values) at randomization.
  • Have active arthritis and/or active rash as defined by the SLEDAI-2K at randomization.

Exclusion criteria

Exclusion Criteria:

  • Have active severe lupus nephritis.
  • Have active severe central nervous system (CNS) lupus.
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking product or interfere with the interpretation of data.
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection.
  • Are currently receiving oral at doses >20-milligrams per day of prednisone (or equivalent) or have adjusted the dose of corticosteroids within 2 weeks of planned randomization.
  • Have started treatment with or adjusted the dose of nonsteroidal anti-inflammatory drugs (NSAIDs) (for which the NSAID use is intended for treatment of signs and symptoms of SLE) within 4 weeks of planned randomization.
  • Have started treatment with or adjusted the dose of an antimalarial within 12 weeks of planned randomization.
  • Have started treatment with or adjusted the dose of an within 12 weeks of planned randomization.
  • Have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    2 mg Baricitinib

    Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.

    Drug: Baricitinib

  • Experimental
    4 mg Baricitinib

    Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.

    Drug: Baricitinib

  • Placebo comparator
    Placebo

    Participants received Placebo orally once daily (QD) for 24 weeks.

    Drug: Placebo

Interventions

  • Administered orally

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

    Participants were defined as responder as follows using SLEDAI-2K definitions of arthritis and rash. If only arthritis is present at baseline, then arthritis must be absent at Week 24 to meet the primary endpoint. If only rash is present at baseline, then rash must be absent at Week 24 to meet the primary endpoint. If both arthritis and rash are present at baseline, then the primary endpoint is met if either arthritis, or rash, or both arthritis and rash are absent at Week 24.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Who Achieve SLE Responder Index 4 (SRI-4) Response

    SRI-4 response is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores; and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in Physician's Global Assessment of Disease Activity. The SRI-4 is a composite index used to assess disease activity in SLE. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe).

    Time frame: Week 24

  2. Change From Baseline in SLEDAI-2K Score

    SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).

    Time frame: Baseline, Week 24

  3. Change From Baseline in Patient's Global Assessment of Disease Activity

    The Patient's Global Assessment of Disease Activity is a single-item, patient reported scale developed for the assessment of the patient's overall rating of their disease activity due to SLE. The scale measures disease activity through a 5 point Likert scale ranging from 0 ("No disease activity") to 4 ("Severe disease activity") at its worst over the past 7 days. LS mean was determined by MMRM model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).

    Time frame: Baseline, Week 24

  4. Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)

    Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. AUC takes all time points post dose into account and one value is reported.

    Time frame: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose

  5. Population Pharmacokinetics (PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss)

    Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. Cmax takes all time points post dose into account and one value is reported.

    Time frame: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose

07

Results

Posted Nov 21, 2018

Participant flow

Participant flow — Overall Study
MilestonePlacebo2 mg Baricitinib4 mg Baricitinib
Started105105104
Received at least 1 dose of study drug105105104
Completed838686
Not completed221918
Withdrew: Adverse event41011
Withdrew: Lack of efficacy930
Withdrew: Lost to follow-up200
Withdrew: Physician decision232
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject534

Outcome measures

PrimaryPercentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

Participants were defined as responder as follows using SLEDAI-2K definitions of arthritis and rash. If only arthritis is present at baseline, then arthritis must be absent at Week 24 to meet the primary endpoint. If only rash is present at baseline, then rash must be absent at Week 24 to meet the primary endpoint. If both arthritis and rash are present at baseline, then the primary endpoint is met if either arthritis, or rash, or both arthritis and rash are absent at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
Percentage of ParticipantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)53.358.167.3
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.392 · Odds ratio (or): 1.28 · 95% CI 0.73 to 2.27
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.041 · Odds ratio (or): 1.84 · 95% CI 1.02 to 3.29
SecondaryPercentage of Participants Who Achieve SLE Responder Index 4 (SRI-4) Response

SRI-4 response is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores; and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in Physician's Global Assessment of Disease Activity. The SRI-4 is a composite index used to assess disease activity in SLE. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe).

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve SLE Responder Index 4 (SRI-4) Response
Percentage of ParticipantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Who Achieve SLE Responder Index 4 (SRI-4) Response47.651.464.4
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.440 · Odds ratio, log: 1.25 · 95% CI 0.71 to 2.19
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.015 · Odds ratio (or): 2.04 · 95% CI 1.15 to 3.62
SecondaryChange From Baseline in SLEDAI-2K Score

SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in SLEDAI-2K Score
Units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in SLEDAI-2K Score-3.82 ± 0.352-4.07 ± 0.356-4.39 ± 0.353
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.600 · Ls mean difference (final vaules): -0.26 · 95% CI -1.23 to 0.71
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.243 · Ls mean difference (final vaules): -0.58 · 95% CI -1.55 to 0.39
SecondaryChange From Baseline in Patient's Global Assessment of Disease Activity

The Patient's Global Assessment of Disease Activity is a single-item, patient reported scale developed for the assessment of the patient's overall rating of their disease activity due to SLE. The scale measures disease activity through a 5 point Likert scale ranging from 0 ("No disease activity") to 4 ("Severe disease activity") at its worst over the past 7 days. LS mean was determined by MMRM model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Patient's Global Assessment of Disease Activity
Units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Patient's Global Assessment of Disease Activity-0.67 ± 0.105-0.83 ± 0.107-1.00 ± 0.105
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.285 · Ls mean difference (final vaules): -0.16 · 95% CI -0.45 to 0.13
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.026 · Ls mean difference (final vaules): -0.33 · 95% CI -0.62 to -0.04
SecondaryPopulation Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)

Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. AUC takes all time points post dose into account and one value is reported.

Time frame:
Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)
nanogram*hour per milliliter (ng*h/mL)2 mg Baricitinib4 mg Baricitinib
Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)265 ± 55569 ± 50
SecondaryPopulation Pharmacokinetics (PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss)

Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. Cmax takes all time points post dose into account and one value is reported.

Time frame:
Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Population Pharmacokinetics (PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss)
nanogram per milliliter (ng/mL)2 mg Baricitinib4 mg Baricitinib
Population Pharmacokinetics (PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss)29.0 ± 3059.2 ± 24

Adverse events

Collected over Up to 32 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/105 (0%)5/105 (4.8%)27/105 (25.7%)
2 mg Baricitinib0/105 (0%)11/105 (10.5%)36/105 (34.3%)
4 mg Baricitinib0/104 (0%)10/104 (9.6%)32/104 (30.8%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventPlacebo2 mg Baricitinib4 mg Baricitinib
PneumoniaInfections and infestations0/1051/1052/104
DepressionPsychiatric disorders0/1050/1052/104
AbortionPregnancy, puerperium and perinatal conditions0/991/960/99
Cervical dysplasiaReproductive system and breast disorders0/991/960/99
DiarrhoeaGastrointestinal disorders0/1050/1051/104
Gastric ulcerGastrointestinal disorders0/1050/1051/104
Intestinal perforationGastrointestinal disorders0/1050/1051/104
NauseaGastrointestinal disorders0/1050/1051/104
AppendicitisInfections and infestations0/1050/1051/104
DiverticulitisInfections and infestations0/1050/1051/104
Most frequent other events
Most frequent other events
EventPlacebo2 mg Baricitinib4 mg Baricitinib
Urinary tract infectionInfections and infestations11/10510/1059/104
Viral upper respiratory tract infectionInfections and infestations4/10510/10510/104
Upper respiratory tract infectionInfections and infestations6/1057/1058/104
PharyngitisInfections and infestations3/1056/1055/104
HeadacheNervous system disorders3/1056/1053/104

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Mean44.9 ± 12.843.2 ± 11.045.0 ± 12.444.3 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Female999699294
Male69520
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Hispanic or Latino383232102
Not Hispanic or Latino526260174
Unknown or Not Reported15111238
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
American Indian or Alaska Native961025
Asian20202060
Native Hawaiian or Other Pacific Islander0000
Black or African American59721
White716865204
More than one race0112
Unknown or Not Reported0112
Region of Enrollment
Region of Enrollment(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Puerto Rico65617
Argentina912728
Austria3238
South Korea1236
Romania42713
United States31343095
Japan13101033
Taiwan67518
Poland1310932
Mexico1181433
France27716
Spain66315
08

Study locations

84 sites
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Wallace Rheumatic Study Center
    Beverly Hills, California 90211, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • TriWest Research Assocaites
    El Cajon, California 92020, United States
  • University of California
    La Jolla, California 92037, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Inlande Rheumatology Clinical Trials
    Upland, California 91786, United States
  • Denver Arthritis Center
    Denver, Colorado 80230, United States
  • New Horizon Research Center
    Miami, Florida 33175, United States
  • West Broward Rheumatology Associates, Inc
    Tamarac, Florida 33321, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • Kansas City Internal Medicine Research
    Overland Park, Kansas 66209, United States
  • The Arthritis & Diabetes Clinic Inc.
    Monroe, Louisiana 71203, United States
  • Louisiana State University Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Clayton Medical Research
    Saint Louis, Missouri 63117, United States
  • Arthritis Consultants
    Saint Louis, Missouri 63141, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • North Shore University Hospital at Great Neck
    Great Neck, New York 11021, United States
  • The Ohio State University
    Columbus, Ohio 43203, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Arthritis & Rheumatology Center of Oklahoma PLLC
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104-5046, United States
  • The Oklahoma Center For Arthritis Therapy
    Tulsa, Oklahoma 74104, United States
  • East Penn Rheumatology
    Bethlehem, Pennsylvania 18015, United States
  • Clinical Research Center of Reading, LLC
    Wyomissing, Pennsylvania 19610, United States
  • Accent Clinical Research Professionals, LLC
    Allen, Texas 75013, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma de Buenos Aire, C1417EYG, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, J5402DIL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel de Tucuman, T4000AXL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel de Tucuman, T4000BRD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Graz, 8036, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wien, 1090, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wien, 1130, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bordeaux, 33076, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13003, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pessac Cedex, 33604, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Strasbourg CEDEX, 67098, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Asahikawa, 070-8644, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chuo-Ku, 104-8560, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 810-8563, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamamatsu, 430-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Itabashi-ku, 173-8610, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kawagoe, 350-8550, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kita-gun, 761-0793, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kitakyushu, 807-8556, Japan
  • Meguro-kuFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Meguro-ku, 153-8515, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagasaki, 852-8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omura, 856-8562, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sapporo, 060-8648, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sasebo, 857-1195, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sendai, 980-8574, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gwangju, 61469, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Incheon, 22332, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 02447, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 03080, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suwon, 16499, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44650, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44690, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 06700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zapopan, 45030, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bydgoszcz, 85-168, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bytom, 41-902, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elblag, 82-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-546, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nadarzyn, 05-830, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Swidnik, 21-040, Poland
  • Office: Perez-De Jesus, Amarilis
    Caguas, 00725, Puerto Rico
  • Mindful Medical Research
    San Juan, 00918, Puerto Rico
  • Latin Clinical Trial Center
    Santurce, 00909, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brasov, 500283, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucuresti, 011172, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Galati, 800587, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Targu Mures, 540136, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Badalona, 08916, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28041, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vigo, 36200, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 83301, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung City, 40201, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 40447, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 10002, Taiwan
09

References and documents

Publications

  • Dorner T, Tanaka Y, Dow ER, Koch AE, Silk M, Ross Terres JA, Sims JT, Sun Z, de la Torre I, Petri M. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022 Aug 11;81(9):1267-1272. doi: 10.1136/annrheumdis-2022-222335. PubMed 35609978 ↗
  • Dorner T, van Vollenhoven RF, Doria A, Jia B, Ross Terres JA, Silk ME, de Bono S, Fischer P, Wallace DJ. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther. 2022 May 16;24(1):112. doi: 10.1186/s13075-022-02794-x. PubMed 35578304 ↗
  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗
  • Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dorner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Erratum In: Lancet. 2018 Aug 11;392(10146):476. doi: 10.1016/S0140-6736(18)31741-0. PubMed 30043749 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Oct 2017, 18 months.

Results were first posted in Nov 2018, 1 year 1 month after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 18 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2016
First posted
Mar 15, 2016
StartActual
Mar 24, 2016
Primary completionActual
Oct 12, 2017
CompletionActual
Nov 9, 2017
Results first posted
Nov 21, 2018
Last update
Nov 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02708095
Responsible party
Sponsor
First posted
Mar 15, 2016
Start date
Mar 24, 2016
Primary completion
Oct 12, 2017
Completion
Nov 9, 2017
Results posted
Nov 21, 2018
Last update
Nov 21, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion